EPICS Therapeutics to acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities

Published: 03.01.2019

Brussels, Belgium, December 21st, 2018

EPICS Therapeutics SA, a recently launched biotech company (April 2018) focused on discovery and development of innovative small molecules anti-cancer drugs acting on RNA epigenetics, today announced it has entered into a Business Transfer Agreement with Ogeda SA. On Dec 31st 2018, part of the Ogeda assets, including research stage programs and the EuroscreenFast Business Services Unit will be acquired by EPICS Therapeutics.  The financial details of the transaction are not disclosed. In parallel of this acquisition, EPICS Therapeutics will also raise €14.2 Million ($16.1 Million) to fund further developments. All current shareholders of EPICS Therapeutics, including Newton BioCapital and SRIW will participate to this new round, and will be joined by new comers including Fund+, SFPI-FPIM, and BNP Paris Fortis Private Equity. Jean Combalbert, PharmD, PhD, who was the former CEO of Ogeda before Astellas Pharma Inc. acquisition, and now CEO of EPICS Therapeutics mentioned, “With this acquisition, EPICS Therapeutics will take a big step forward that will allow us to accelerate our development over the next years, creating a world leading epidrugs’ company with capabilities and resources with successful track-record, including highly qualified staff”.



Jean Combalbert, PharmD, PhD
jcombalbert@epicstx.com (from Jan 1st 2019)
+32 485 339 876

François Fuks, PhD
ffuks@epicstx.com (from Jan 1st 2019)
+32 485 382 313